David Ross Camidge, MD, PhD, is the Director of the Thoracic Oncology Clinical Program and the Program Director for the Thoracic Oncology Clinical and Translational Research Fellowship at the University of Colorado School of Medicine.
Dr Camidge obtained a PhD degree in Molecular Biology at the Medical Research Council’s Laboratory of Molecular Biology at Cambridge University, Cambridge, UK. He then completed his medical training at Oxford University, Oxford, UK, and became the first person to double train in Medical Oncology and Clinical Pharmacology in the UK.
Dr Camidge’s main areas of clinical and research interest are thoracic malignancies and developmental therapeutics. He serves as the principal investigator on numerous trials, both on the national and international levels. Dr Camidge is an advocate for lung cancer patients getting the latest drugs available via clinical trials, and much of his research focuses on the optimization of new agents by means of personalized medicine.
He has authored or co-authored over 200 articles published in peer-reviewed, scientific journals around novel therapies and thoracic malignancies. In 2013 he became the first physician to receive the Hank Baskett Sr. Spirit Award. In 2017 and 2018, he was internationally recognized as a highly cited researcher ranked in the top 1% of all of Clinical Medicine by Clarivate Analytics Web of Science.